Pulmonary Mycobacteriosis caused by Rifampicin-resistant Mycobacterium szulgai.

Nakayama, Seiko; Fujii, Takeshi; Kadota, Jun‐ichi; Sawa, Hideaki; Hamabe, Sadanori; Tanaka, Toshiro; Mochinaga, Nobuo; Tomono, Kazunori; Kohno, Shigeru

doi:10.2169/internalmedicine.39.309

Cited by 9 publications

(6 citation statements)

References 13 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mycobacterium szulgai is susceptible in vitro to most antituberculosis drugs, as well as to fluoroquinolones and macrolides. 83,84 Although the optimal duration of therapy has not been delineated, a 3-or 4-drug regimen that includes 12 months of negative sputum cultures while on therapy appears adequate. 37 Mycobacterium xenopi has variable drug susceptibility testing results that are hard to interpret, especially regarding the first-line antituberculous agents.…”

Section: Malmoense M Szulgai and M Xenopi Lung Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

When and how to treat pulmonary non‐tuberculous mycobacterial diseases

Thomson¹,

Yew

2008

Respirology

View full text Add to dashboard Cite

Non-tuberculous mycobacteria are ubiquitous environmental organisms that have been recognized as a cause of pulmonary infection for over 50 years. Traditionally patients have had underlying risk factors for development of disease; however, the proportion of apparently immunocompetent patients involved appears to be rising. Not all patients culture-positive for mycobacteria will have progressive disease, making the diagnosis difficult, though criteria to aid in this process are available. The two main forms of disease are cavitary disease (usually involving the upper lobes) and fibronodular bronchiectasis (predominantly middle and lingular lobes). For patients with disease, combination antibiotic therapy for 12-24 months is generally required for successful treatment, and this may be accompanied by drug intolerances and sideeffects. Published success rates range from 30% to 82%. As the progression of disease is variable, for some patients, attention to pulmonary hygiene and underlying diseases without immediate antimycobacterial therapy may be more appropriate. Surgery can be a useful adjunct, though is associated with risks. Randomized controlled trials in well-described patients would provide stronger evidence-based data to guide therapy of non-tuberculous mycobacteria lung diseases, and thus are much needed.

show abstract

Section: Malmoense M Szulgai and M Xenopi Lung Diseasesmentioning

confidence: 99%

“…Mycobacterium szulgai is susceptible in vitro to most antituberculosis drugs, as well as to fluoroquinolones and macrolides 83,84 . Although the optimal duration of therapy has not been delineated, a 3‐ or 4‐drug regimen that includes 12 months of negative sputum cultures while on therapy appears adequate 37 …”

Section: How To Treat Pulmonary Ntm Diseasesmentioning

confidence: 99%

When and how to treat pulmonary non‐tuberculous mycobacterial diseases

Thomson¹,

Yew

2008

Respirology

View full text Add to dashboard Cite

show abstract

“…Three case reports describe multidrug resistance to isoniazid, rifampin, ethambutol, and pyrazinamide in various combinations. 1,19,20 However, to our knowledge, our patient is the first to exhibit resistance to all four of these agents. As the primary manifestation of M. szulgai is pulmonary disease, patients are often empirically treated with antituberculosis drugs.…”

Section: Discussionmentioning

confidence: 70%

Mycobacterium szulgai in a Patient with Advanced Acquired Immunodeficiency Syndrome: An Unusual Pathogen with Unusual Multidrug Resistance

Prichard

2006

Pharmacotherapy

View full text Add to dashboard Cite

A 37-year-old Hispanic man with advanced acquired immunodeficiency syndrome developed extensive pulmonary disease with persistent cough, fever, night sweats, worsening dyspnea, and weight loss. Sputum samples showed scant growth of acid-fast bacilli. He failed to respond to the standard tuberculosis regimen of isoniazid, rifampin, ethambutol, and pyrazinamide. Subsequently, Mycobacterium szulgai was identified, and susceptibility tests showed it to be resistant to all four of those agents. Therapy was changed to clarithromycin, doxycycline, ciprofloxacin, and amikacin. Within 2 weeks, the patient's condition improved significantly, and 6 months after treatment, extensive pulmonary infiltrates had nearly resolved. Fewer than 1% of all human isolates of mycobacteria consist of M. szulgai, which is relatively susceptible to standard antimycobacterial agents. To our knowledge, this is the first reported case of M. szulgai with resistance to all primary antituberculosis drugs.

show abstract

“…Because M. szulgai is rarely recovered from the environment, cultures yielding M. szulgai almost always have a pathological significance. M. szulgai has been reported from a small number of cases in the English-language literature as a human pathogen (424)(425)(426)(427)(428).…”

Section: Szulgaimentioning

confidence: 99%

Metabolomic Insights into Tuberculosis: Machine Learning Approaches for Biomarker Identification

2023

IJMCB

View full text Add to dashboard Cite

The lung parenchyma is largely impacted by the infectious condition known as pulmonary tuberculosis (pulmonary TB) when the immune system creates a wall around the germs in the lungs, a tiny, hard bulge known as a tubercle develops, earning the disease the name tuberculosis. Although the majority of TB germs target the lungs, they can also harm other bodily organs. The identification of TB biomarkers, which are crucial for diagnosis, treatment monitoring, risk analysis, and prognosis, has been the subject of extensive research. Differences in metabolites between normal cells and tuberculosis are considered to be able to support the diagnosis of tuberculosis. Metabolite data was taken from the Metabolomic workbench and further identification and prediction were carried out in silico. A total of 44 samples found 69 metabolites which were then carried out further analysis. Found as many as 5 metabolites that play an important role in tuberculosis. Of the 5 metabolites, 2 candidate biomarkers were found which are known to have potential as biomarkers. The candidate biomarkers for these metabolites are trans-3-methyluric acid and nicotinic acid. However, this simulation needs further testing to obtain more accurate biomarkers and support the diagnosis.

show abstract

Pulmonary Mycobacteriosis caused by Rifampicin-resistant Mycobacterium szulgai.

Cited by 9 publications

References 13 publications

When and how to treat pulmonary non‐tuberculous mycobacterial diseases

When and how to treat pulmonary non‐tuberculous mycobacterial diseases

Mycobacterium szulgai in a Patient with Advanced Acquired Immunodeficiency Syndrome: An Unusual Pathogen with Unusual Multidrug Resistance

Metabolomic Insights into Tuberculosis: Machine Learning Approaches for Biomarker Identification

Contact Info

Product

Resources

About